Gossamer Bio Files 8-K: Board Changes & Shareholder Votes

Ticker: GOSS · Form: 8-K · Filed: 2025-06-25T00:00:00.000Z

Sentiment: neutral

Topics: governance, executive-compensation, shareholder-vote

TL;DR

Gossamer Bio board shakeup and shareholder votes incoming.

AI Summary

Gossamer Bio, Inc. announced on June 25, 2025, changes in its board of directors and executive compensation arrangements. The filing also covers the submission of matters to a vote of security holders, indicating potential shareholder decisions on corporate governance or strategic initiatives.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy or governance, while shareholder votes directly impact corporate direction.

Risk Assessment

Risk Level: medium — Changes in board and executive compensation, along with shareholder votes, can introduce uncertainty and potential shifts in company strategy.

Key Players & Entities

Gossamer Bio, Inc. (company) — Registrant
June 25, 2025 (date) — Date of earliest event reported

FAQ

What specific changes were made to the board of directors?

The filing indicates a change in directors, specifically mentioning the departure of certain officers and the election of new directors, but does not detail the names or specific roles in this section.

What are the details of the compensatory arrangements for certain officers?

The filing notes that compensatory arrangements for certain officers are being disclosed, but the specific details of these arrangements are not provided within this summary section.

What matters were submitted to a vote of security holders?

The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not specified in this section.

When was the report filed?

The report was filed as of June 25, 2025.

What is Gossamer Bio, Inc.'s state of incorporation?

Gossamer Bio, Inc. is incorporated in Delaware.

From the Filing

0001728117-25-000043.txt : 20250625 0001728117-25-000043.hdr.sgml : 20250625 20250625160112 ACCESSION NUMBER: 0001728117-25-000043 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250625 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20250625 DATE AS OF CHANGE: 20250625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Gossamer Bio, Inc. CENTRAL INDEX KEY: 0001728117 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 475461709 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38796 FILM NUMBER: 251073587 BUSINESS ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 684-1300 MAIL ADDRESS: STREET 1: 3115 MERRYFIELD ROW STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 goss-20250625.htm 8-K goss-20250625 0001728117 FALSE 0001728117 2025-06-25 2025-06-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 GOSSAMER BIO, INC. (Exact name of Registrant as Specified in Its Charter)   Delaware 001-38796 47-5461709 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       3115 Merryfield Row, Suite 120 San Diego , California , 92121 (Address of Principal Executive Offices) (Zip Code) ( 858 ) 684-1300 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   GOSS   Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The 2025 annual meeting of stockholders of Gossamer Bio, Inc. (the “Company”) was held on June 25, 2025 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved the Amended and Restated 2019 Incentive Award Plan (the “Amended and Restated 2019 Plan”). The Amended and Restated 2019 Plan was approved by the Company’s Board of Directors (the “Board”) on March 24, 2025, subject to stockholder approval at